Haslam D
The Cheyne Society, Datchworth, UK.
Int J Clin Pract. 2016 Mar;70(3):206-17. doi: 10.1111/ijcp.12771. Epub 2016 Jan 26.
To describe the treatment of obesity from ancient times to present day.
Articles reporting the development of anti-obesity therapies were identified through a search for 'anti-obesity' AND 'pharmacotherapy' AND 'development' within the title or abstract on PubMed and 'obesity' in ClinicalTrials.gov. Relevant articles and related literature were selected for inclusion.
Stone-age miniature obese female statuettes indicate the existence and cultural significance of obesity as long as 30,000 years ago. Records from Ancient Egyptian and Biblical eras through Greco-Roman to Medieval times indicate that obesity was present throughout the major periods of history, although peoples of previous centuries would probably have experienced overweight and obesity as exceptional rather than normal. Health risks of obesity were noted by the Greek physician Hippocrates (460-377 BCE) when the earliest anti-obesity recommendations on diet, exercise, lifestyle and use of emetics and cathartics were born. These recommendations remained largely unchanged until the early 20th century, when spreading urbanisation, increasingly sedentary jobs and greater availability of processed foods produced a sharp rise in obesity. This led to the need for new, more effective, ways to lose weight, to address comorbidities associated with obesity, and to attain the current cultural ideal of slimness. Drug companies of the 1940s and 1950s produced a series of anti-obesity pharmacotherapies in short succession, based largely on amphetamines. Increased regulation of drug development in the 1960s and new efficacy requirements for weight-loss drugs led to rapid reduction in anti-obesity therapies available by the early 1990s.
In the last two decades, several new and emerging therapies have been approved or are in development to provide safe, long-term pharmacological agents for the treatment of obesity.
描述从古至今肥胖症的治疗情况。
通过在PubMed的标题或摘要中搜索“抗肥胖”“药物治疗”和“发展”,以及在ClinicalTrials.gov中搜索“肥胖症”,识别报告抗肥胖疗法发展的文章。选择相关文章及相关文献纳入研究。
石器时代的微型肥胖女性小雕像表明,肥胖症在3万年前就已存在并具有文化意义。从古埃及和圣经时代到希腊罗马时代再到中世纪的记录表明,肥胖症在历史的主要时期都存在,尽管前几个世纪的人们可能将超重和肥胖视为例外而非正常现象。希腊医生希波克拉底(公元前460 - 377年)指出了肥胖症的健康风险,同时诞生了最早关于饮食、运动、生活方式以及使用催吐剂和泻药的抗肥胖建议。这些建议在很大程度上一直未变,直到20世纪初,城市化的蔓延、越来越多的久坐工作以及加工食品的更多供应导致肥胖症急剧增加。这就需要新的、更有效的减肥方法,以解决与肥胖症相关的合并症,并实现当前文化所推崇的苗条理想。20世纪40年代和50年代的制药公司接连推出了一系列主要基于安非他明的抗肥胖药物疗法。20世纪60年代对药物研发的监管加强以及对减肥药物新的疗效要求,导致到20世纪90年代初可用的抗肥胖疗法迅速减少。
在过去二十年中,几种新出现的疗法已获批准或正在研发中,以提供用于治疗肥胖症的安全、长期的药物制剂。